UNSPSC 51384207: Fenoprofen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 869607J16Q, chemically known as benzeneacetic acid, .alpha.-methyl-3-phenoxy-, sodium salt (1:1), but more generally known as fenoprofen sodium, which bears US NIH Compound Identifier 60897. European Medicines Agency schedules fenoprofen sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07578MIG.

Most nations, for tariff purposes, schedule fenoprofen sodium under HS 29189900. SMILES: CC(C1CCCC(C1)OC2CCCCC2)C(=O)[O-].[NA+].

UNSPSC 51384207 Fenoprofen sodium is a Commodity code that in practice captures pharmaceutical procurement across state and local health agencies, though recent opportunities show minimal activity directly tagged to this specific drug product. The recent opportunities instead reflect broader pharmaceutical procurement patterns: state and local governments are buying naloxone and drug-deactivation systems for community health initiatives, generic multi-source pharmaceuticals and OTC products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription programs to manage pharmacy benefit costs. The issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple participating states including Oregon). These jurisdictions are seeking vendors capable of meeting drug supply chain security compliance, FDA registration, cGMP certification, and wholesaler network integration.

Recent activity concentrates in Florida and Texas with multistate cooperative purchasing extending across the upper Midwest and Pacific Northwest. A representative opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023 — note the date discrepancy in source), which seeks 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries and fixed-fee pricing. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state interest in bypassing traditional PBM and GPO intermediaries. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products requires vendor compliance with DSCSA and cGMP, authorized-wholesaler network participation, and carries performance penalties of $200 to $1,500 per violation. The code shows limited direct procurement activity for fenoprofen sodium specifically; state and local pharmaceutical buying is driven by broader category buys, cooperative vehicles, and emerging direct-procurement models rather than targeted single-ingredient procurements.